News and Announcements
MHRA Approves Commencement of OncoSil’s Study of Pancreatic Cancer Clinical Study in UK
- Published February 21, 2017 11:32AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX:OSL) is a medical device company seeking to advance radiation for cancer patients.
KEY TAKEAWAYS:
- Medical device company is mainly focused on localised treatments for patients with pancreatic and liver cancer.
- MHRA has approved the commencement of the Pancreatic Cancer Clinical Study in the UK.
OncoSil Medical Limited is a clinical-stage Australian Lifesciences company with the aim to develop and provide technologies for safer medical radiation treatments.
“The comprehensive MHRA review conducted over the past two months, focused on pre-clinical, clinical data as well study design. Approval was granted with no objections raised.
Daniel Kenny, CEO commented:
We are delighted with this news, which is a further endorsement of our clinical data package and allows OncoSil Medical to commence Clinical Studies in the UK.”
OncoSil Medical hopes with treatment of OncoSil™ it will deliver a more concentrated localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy.
To view the full ASX Announcement, please click here.